Skip to main content

Vaccitech plc (VACC)

NASDAQ: VACC · IEX Real-Time Price · USD
14.37
+0.11 (0.77%)
After-hours:Oct 22, 2021 4:00 PM EDT
14.26
-0.49 (-3.32%)
At close: Oct 22, 4:00 PM
Market Cap497.76M
Revenue (ttm)3.85M
Net Income (ttm)n/a
Shares Out34.33M
EPS (ttm)-9.52
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume14,937
Open14.75
Previous Close14.75
Day's Range14.25 - 14.75
52-Week Range12.25 - 17.99
Betan/a
AnalystsBuy
Price Target24.50 (+71.8%)
Est. Earnings DateNov 11, 2021

About VACC

Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. We use our proprietary platform to develop product candidates that stimulate powerful, targeted immune responses against pathogens and tumor cells. We design our product candidates to stimulate immune responses that are robust, highly specific, and are differentiated by the magnitude of the T cell populations induced, which exhibit critical f...

IndustryBiotechnology
IPO DateApr 30, 2021
CEOWilliam Enright
Employees48
Stock ExchangeNASDAQ
Ticker SymbolVACC
Full Company Profile

Financial Performance

In 2020, Vaccitech's revenue was $4.82 million, a decrease of -29.58% compared to the previous year's $6.85 million. Losses were -$17.71 million, -14.59% less than in 2019.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Vaccitech stock is "Buy." The 12-month stock price forecast is 24.50, which is an increase of 71.81% from the latest price.

Price Target
$24.50
(71.81% upside)
Analyst Consensus: Buy

News

Vaccitech Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter, ended June 30, 2021, and provided an overview of the ...

2 months ago - GlobeNewsWire

Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B

Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatitis B virus who are already receiving standard-of-care...

Other symbols:ABUS
3 months ago - Benzinga

Vaccitech Reports First Quarter 2021 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics an...

4 months ago - GlobeNewsWire

Vaccitech Announces Closing of $110.5 Million Initial Public Offering

OXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and...

5 months ago - GlobeNewsWire

VACC Stock IPO: 7 Things to Know as Vaccitech Starts Trading Today

Here's how VACC stock has performed thus far following the company's highly anticipated IPO in the market today. The post VACC Stock IPO: 7 Things to Know as Vaccitech Starts Trading Today appeared firs...

5 months ago - InvestorPlace

Vaccitech Announces Pricing of Initial Public Offering

OXFORD, United Kingdom, April 29, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (“Vaccitech”) (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immuno...

5 months ago - GlobeNewsWire

Vaccitech, startup behind AstraZeneca-Oxford's COVID-19 vaccine, files for U.S. IPO

Biotech startup Vaccitech Plc, which owns the technology behind the COVID-19 vaccine developed by Oxford University and AstraZeneca Plc, filed for a U.S. initial public offering on Friday.

6 months ago - Reuters

Vaccitech IPO Registration Document (S-1)

Vaccitech plc has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC

AstraZeneca vaccine co-inventors' float on US market is a blow to the UK - but it's not all bad news

Vaccitech's decision to float in the US is a blow to the UK but its success reveals some important and reassuring developments.

6 months ago - Sky News

AstraZeneca vaccine scientists set for £22m payday in New York float

Sarah Gilbert, Adrian Hill and Oxford University to get windfalls when Covid vaccine firm Vaccitech goes public

6 months ago - The Guardian